## ASTHMA

### Genome-wide linkage analysis of pulmonary function in families of children with asthma in Costa Rica


**Background:** Although asthma is highly prevalent among certain Hispanic subgroups, genetic determinants of asthma and asthma-related traits have not been conclusively identified in Hispanic populations. A study was undertaken to identify genomic regions containing susceptibility loci for pulmonary function and bronchodilator responsiveness (BDR) in Costa Ricans.

**Methods:** Eight extended pedigrees were ascertained through schoolchildren with asthma in the Central Valley of Costa Rica. Short tandem repeat (STR) markers were genotyped throughout the genome at an average spacing of 8.2 cM. Multipoint variance component linkage analyses of forced expiratory volume in 1 second (FEV$_1$) and FEV$_1$/forced vital capacity (FVC); both pre-bronchodilator and post-bronchodilator) and BDR were performed in these eight families (pre-bronchodilator spirometry, $n=640$; post-bronchodilator spirometry and BDR, $n=624$). Nine additional STR markers were genotyped on chromosome 7. Secondary analyses were repeated after stratification by cigarette smoking.

**Results:** Among all subjects, the highest logarithm of the odds of linkage (LOD) score for FEV$_1$ (post-bronchodilator) was found on chromosome 7q34–35 (LOD = 2.45, including the additional markers). The highest LOD scores for FEV$_1$/FVC (pre-bronchodilator) and BDR were found on chromosomes 2q (LOD = 1.53) and 9p (LOD = 1.53), respectively. Among former and current smokers there was near-significant evidence of linkage to FEV$_1$/FVC (post-bronchodilator) on chromosome 5p (LOD = 3.27) and suggestive evidence of linkage to FEV$_1$ on chromosomes 3q (pre-bronchodilator, LOD = 2.74) and 4q (post-bronchodilator, LOD = 2.66).

**Conclusions:** In eight families of children with asthma in Costa Rica, there is suggestive evidence of linkage to FEV$_1$ on chromosome 7q34–35. In these families, FEV$_1$/FVC may be influenced by an interaction between cigarette smoking and a locus (loci) on chromosome 5p.

Spirometric measurements of pulmonary function are important markers of asthma severity and critical intermediate phenotypes for asthma research. Several groups have identified genomic regions linked to pulmonary function measurements (such as forced expiratory volume in 1 second (FEV$_1$) and FEV$_1$/forced vital capacity (FVC) ratio) in families ascertained through probands with asthma. The prevalence and severity of asthma are markedly variable among different Hispanic populations living in the US and Latin America, and these differences may have an underlying genetic component. In the Collaborative Study on the Genetics of Asthma, genome-wide linkage analysis of asthma and some of its intermediate phenotypes (e.g., total serum IgE) were performed in Hispanic families from New Mexico. However, there has been no genome-wide linkage analysis of pulmonary function phenotypes in any Hispanic population.

Bronchodilators, specifically β$_2$-adrenergic receptor agonists, are the most widely prescribed drugs in the treatment of asthma. There is a substantial inter-individual variation in the response to inhaled β$_2$-agonists, and bronchodilator responsiveness (BDR) has been shown to aggregate in families, consistent with a genetic component to the variation in BDR. Although multiple studies have examined genetic linkage for airway responsiveness to bronchoconstrictor agents or pre-bronchodilator and post-bronchodilator spirometry measurements, a genome-wide linkage analysis of BDR in families with asthma has not been published. The only reported linkage analysis for BDR was in families of probands with severe, early-onset chronic obstructive disease (COPD).

In this study, we performed genome-wide linkage analyses of pulmonary function measurements and BDR in families of children with asthma in Costa Rica, a nation with a high prevalence of childhood asthma. Most Costa Ricans live in the Central Valley, where there is a genetically isolated population of predominantly mixed Spanish and Amerindian origin. Extensive genealogical records can be used to track the rapid expansion of this population from approximately 4000 found-individuals registered in the census of 1697 to about 2.85 million current residents of the Central Valley. The unique characteristics of the population of the Central Valley make it ideal for studies of the genetics of asthma and/or its intermediate phenotypes.

### METHODS

**Study subjects**

Seven probands were recruited through an ongoing study of children with asthma; an eighth proband was recruited from phase II of the International Study of Asthma and Allergies in Childhood in Costa Rica. Eligible probands were 6–12 years old and had physician-diagnosed asthma, ≥2 respiratory symptoms per week, or at least one asthma exacerbation requiring medication in the preceding 12 months.

**Abbreviations:** BDR, bronchodilator responsiveness; COPD, chronic obstructive pulmonary disease; FEV$_1$, forced expiratory volume in 1 second; FVC, forced vital capacity; LOD, logarithm of the odds of linkage; SOLAR, Sequential Oligogenic Linkage Analysis Routines; STR, short tandem repeat

See end of article for authors’ affiliations

**Correspondence to:**
Dr J C Celedón, Channing Laboratory, Brigham and Women’s Hospital, 181 Longwood Avenue, Boston, MA 02115, USA; juan.celedon@channing.harvard.edu

Received 29 June 2006
Accepted 27 September 2006
Published Online First 10 November 2006


www.thoraxjnl.com

Copyright © Rsospho 2007. Published by BMJ Publishing Group Ltd.
markers were located at an average spacing of 8.2 cM. A human screening set 6.5% (p = 3 × 10−6). Results are expressed as logarithm of the odds of linkage (LOD) scores [log10 [base 10] of the odds of linkage versus no linkage]. Covariates included age, sex, height, weight, smoking status (ever vs never) and pack-years of cigarette smoking, including quadratic terms for continuous variables. Significant covariates (p < 0.05) were included in the linkage models. Only 19 subjects (3%) were using anti-inflammatory drugs for asthma, so drug usage was not included as a covariate. Multipoint identity-by-descent matrices were estimated by a Markov-Chain Monte Carlo algorithm implemented in the Loki program. Because of potential misclassification of chronic obstructive pulmonary disease (COPD) as asthma, secondary analyses were performed in non-smokers only by removing the phenotype measurements of current and former smokers, and in smokers-only by removing the phenotypes of non-smokers.

Log10 transformed BDR and raw FEV1 measurements had acceptable kurtosis after adjustment for covariates in the final variance component models. Because of residual kurtosis (>3), FEV1/FVC measurements were analysed by the t-distribution in SOLAR. Empirical p values for the multipoint LOD scores were estimated by comparing the observed LOD scores with the empirical distribution of LOD scores resulting from 100 000 simulations in SOLAR.

One thousand simulations were run in SOLAR to assess our statistical power to detect linkage (LOD scores ranging from >1 to >3) to a biallelic locus influencing a quantitative trait with heritability ranging from 10% to 25% in the Costa Rican pedigrees. These simulations assumed that the trait of interest was influenced by a single quantitative trait locus and that fully informative marker data were available for study subjects.

RESULTS

Study subjects

Of the 667 members of the eight participating families, 640 and 624 had spirometric measurements of lung function before and after administration of albuterol, respectively (table 1). There was marked variability among participating families in family size, percentage of former and current smokers and percentage of patients with asthma. As expected in individuals with asthma and their relatives with and without asthma, average values of FEV1 and FEV1/FVC were within the normal range. However, post-bronchodilator values were improved.

Analysis of FEV1

After adjustment for significant covariates (table 2), narrow-sense heritability (h2N, the proportion of phenotypic variance explained by genetic factors) for pre-bronchodilator FEV1 was 24.0% (SD 6.8%; p = 6 × 10−6). Heritability was similar for post-bronchodilator measurements of FEV1 (h2N = 23.0% (SD 6.5%), p = 3 × 10−5).

Table 2 lists the highest LOD scores from the genome-wide linkage analyses of FEV1 in all subjects, in non-smokers and in
smokers only; full results are available in Supplementary table 1 (available online at http://thorax.bmj.com/supplemental). In the genome-wide linkage analysis of pre-bronchodilator FEV1 in all subjects, the highest LOD score (1.63 at 127 cM) was found on chromosome 6q. Four additional genomic regions (chromosomes 4q, 6p, 7p and 16q) showed modest evidence of linkage (LOD >1) to pre-bronchodilator FEV1. After excluding the phenotypic data of former and current smokers from the analysis, there was only modest evidence of linkage to pre-bronchodilator FEV1 on chromosomes 4q and 9q. In smokers only, the highest LOD score was on chromosome 3q (LOD = 2.45 at 152 cM) and modest evidence to pre-bronchodilator FEV1 on chromosomes 4q and 7q. Among non-smokers only, chromosomes 1p, 7q and 8p all showed suggestive evidence of linkage in some regions.

In the genome-wide linkage analysis of post-bronchodilator FEV1, in all subjects, there was suggestive evidence of linkage to chromosome 7q (LOD = 2.14) and modest evidence of linkage (LOD >1) to chromosomes 1p, 2p, 15q and 16q. Nine additional STR markers were genotyped on chromosome 7q, the region with the highest LOD score in the analyses of all subjects. With the additional markers, the LOD score for post-bronchodilator FEV1 increased to 2.45 (at 152 cM) in all subjects (fig 1). Among non-smokers only, chromosomes 1p, 7q and 14q showed modest evidence of linkage to post-bronchodilator FEV1. After inclusion of additional markers on chromosome 7q, there was suggestive evidence of linkage (LOD = 2.14) in non-smokers. Chromosomes 2p, 4q (LOD = 2.66 at 138 cM), 8p and 14q all showed suggestive evidence of linkage in smokers only.

### Table 1: Characteristics of families of children with asthma

<table>
<thead>
<tr>
<th>Family</th>
<th>Individuals</th>
<th>Former and current smokers* n [%]</th>
<th>Asthma† n [%]</th>
<th>Mean (SD) FEV1, % predicted‡</th>
<th>Mean (SD) FEV1/FVC, % predicted‡</th>
<th>Mean (SD) bronchodilator response§</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>34</td>
<td>8 (23.5)</td>
<td>12 (35.3)</td>
<td>96.1 (16.8)</td>
<td>101.1 (13.5)</td>
<td>94.5 (8.7)</td>
</tr>
<tr>
<td>2</td>
<td>18</td>
<td>4 (22.2)</td>
<td>7 (38.9)</td>
<td>103.9 (24.0)</td>
<td>109.2 (27.4)</td>
<td>97.8 (6.9)</td>
</tr>
<tr>
<td>3</td>
<td>224</td>
<td>37 (16.5)</td>
<td>56 (25.1)</td>
<td>96.6 (14.8)</td>
<td>100.3 (14.5)</td>
<td>95.8 (7.0)</td>
</tr>
<tr>
<td>4</td>
<td>97</td>
<td>17 (17.5)</td>
<td>16 (16.5)</td>
<td>102.6 (17.4)</td>
<td>107.0 (17.0)</td>
<td>96.9 (8.0)</td>
</tr>
<tr>
<td>5</td>
<td>8</td>
<td>5 (62.5)</td>
<td>2 (28.6)</td>
<td>100.1 (13.2)</td>
<td>102.5 (13.4)</td>
<td>98.1 (7.7)</td>
</tr>
<tr>
<td>6</td>
<td>107</td>
<td>10 (9.4)</td>
<td>8 (7.5)</td>
<td>99.7 (16.4)</td>
<td>102.7 (16.0)</td>
<td>98.5 (6.7)</td>
</tr>
<tr>
<td>7</td>
<td>23</td>
<td>9 (39.1)</td>
<td>5 (21.7)</td>
<td>103.9 (12.4)</td>
<td>108.8 (11.4)</td>
<td>98.1 (5.6)</td>
</tr>
<tr>
<td>8</td>
<td>129</td>
<td>12 (9.3)</td>
<td>24 (18.6)</td>
<td>96.8 (13.9)</td>
<td>100.0 (13.1)</td>
<td>96.9 (8.7)</td>
</tr>
<tr>
<td>All</td>
<td>640</td>
<td>160 (16.0)</td>
<td>130 (20.4)</td>
<td>98.5 (15.8)</td>
<td>102.3 (15.4)</td>
<td>98.6 (7.6)</td>
</tr>
</tbody>
</table>

FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; BD, bronchodilator.

* n=638 individuals with complete data on smoking.
† Physician-diagnosed asthma and wheezing within the past year. n=637 subjects with complete data.
‡ Based on prediction equations for Mexican-Americans in Hankinson et al.23
§ As a percentage of baseline FEV1 (BDRbase).

### Analysis of FEV1/FVC

The estimated heritability was 19.9% (SD 7.8%; p = 2 x 10^{-4}) for pre-bronchodilator values of FEV1/FVC ratio and 15.4% (SD 6.6%; p = 0.001) for post-bronchodilator values. Table 2 and Supplementary table 2 (available online at http://thorax.bmj.com/supplemental) show the results of the genome-wide linkage analysis of FEV1/FVC. In the genome-wide linkage analysis of pre-bronchodilator FEV1/FVC in all subjects, the highest LOD score was on chromosome 2q (LOD = 1.53 at 245 cM). There was also modest evidence of linkage to pre-bronchodilator FEV1/FVC on chromosomes 4q and 7q. Among non-smokers there was modest evidence of linkage to pre-bronchodilator FEV1/FVC on chromosomes 2p, 3q, 4q (LOD = 1.50 at 95 cM), 6p, 7q and 13q. In smokers only the highest LOD score was on chromosome 9q (LOD = 1.52 at 72 cM).

For post-bronchodilator measurements of FEV1/FVC, the highest LOD score in all subjects was on chromosome 7p (LOD = 1.40 at 74 cM). There was also modest evidence of linkage to post-bronchodilator FEV1/FVC on chromosomes 4q and 7q. Among non-smokers there was modest evidence of linkage to post-bronchodilator FEV1/FVC on chromosomes 2p, 3q, 4q, 6p, 7p and 18q. In smokers only the LOD score of 3.27 on chromosome 5p (49 cM) approached genome-wide significant evidence of linkage.24

### Analysis of bronchodilator responsiveness

The three measures of bronchodilator responsiveness (log_{10} transformed) were significantly heritable (BDRbase: h^2_N = 10.3% (SD

### Table 2: Genome-wide linkage analysis for FEV1 and FEV1/FVC in all subjects, non-smokers and smokers only

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Bronchodilator</th>
<th>Subjects</th>
<th>Covariates</th>
<th>Chromosome</th>
<th>cM</th>
<th>LOD</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV1</td>
<td>Pre</td>
<td>All</td>
<td>Age, age², ht, ht², wt, gender, smoker</td>
<td>6</td>
<td>127</td>
<td>1.63</td>
<td>0.004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Non-smokers</td>
<td>Age, age², ht, ht², wt, gender</td>
<td>9</td>
<td>153</td>
<td>1.09</td>
<td>0.014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Smokers</td>
<td>Age, age², ht, gender</td>
<td>3</td>
<td>241</td>
<td>2.74</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Post</td>
<td>All</td>
<td>Age, age², ht, ht², wt, gender</td>
<td>7</td>
<td>150</td>
<td>2.13</td>
<td>0.002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Non-smokers</td>
<td>Age, age², ht, ht², wt, gender</td>
<td>7</td>
<td>150</td>
<td>1.73</td>
<td>0.003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Smokers</td>
<td>Age, age², ht, gender</td>
<td>4</td>
<td>138</td>
<td>2.66</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>FEV1/FVC</td>
<td>Pre</td>
<td>All</td>
<td>Age</td>
<td>2</td>
<td>245</td>
<td>1.53</td>
<td>0.004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Non-smokers</td>
<td>Age, ht</td>
<td>4</td>
<td>95</td>
<td>1.50</td>
<td>0.004</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Smokers</td>
<td>Age, age²</td>
<td>9</td>
<td>72</td>
<td>1.52</td>
<td>0.002</td>
</tr>
<tr>
<td></td>
<td>Post</td>
<td>All</td>
<td>Age, age², ht, wt</td>
<td>7</td>
<td>74</td>
<td>1.40</td>
<td>0.007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Non-smokers</td>
<td>Age, ht, wt</td>
<td>18</td>
<td>117</td>
<td>1.46</td>
<td>0.006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Smokers</td>
<td>Age, age², packs</td>
<td>5</td>
<td>49</td>
<td>3.27</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; BD, bronchodilator.
Age², ht² and wt² represent the quadratic terms for age, height and weight, respectively.
The maximum LOD score for each analysis is reported. Full results are available in supplementary tables 1 and 2.
6.1%), p = 0.01; BDRpred: $h^2_N = 10.4\%$ (SD 6.1%), p = 0.01; BDRabs: $h^2_N = 8.0\%$ (SD 5.6%), p = 0.04), although the heritability estimates were lower than those of the pulmonary function measures. No covariates were significant in the variance component models of the three BDR outcomes in all subjects and in non-smokers. In the genome-wide linkage analysis of BDRbase (log$10$ transformed), the highest LOD score was found on chromosome 4q (LOD = 1.26 at 70 cM; table 3 and supplementary table 3 (available online at http://thorax.bmj.com/supplemental)). A LOD score >1 was found in this location in the analysis of BDRpred. In the analyses of BDRpred and BDRabs, the highest LOD scores were found on chromosome 9p at 49 cM (BDRpred: LOD = 1.25, BDRabs: LOD = 1.53). Despite the reduced sample size, the LOD scores were increased on chromosomes 4q and 9p in analyses restricted to non-smokers only. In non-smokers only, a region on chromosome 10p had LOD scores >1 for all three BDR phenotypes. In smokers, regions on chromosomes 12q and 16q had LOD scores >1 for all three BDR measures.

**Statistical power**

Our statistical power to detect a LOD score >1 was 42% for traits with $h^2_N = 10\%$ (eg, BDRbase) and 98% for traits with $h^2_N = 25\%$ (eg, pre-bronchodilator FEV$_1$). For LOD scores >2, our power ranged from 13.6% for traits with $h^2_N = 10\%$ to 87% for traits with $h^2_N = 25\%$. Finally, our power to detect a LOD score >3 ranged from 4% for traits with $h^2_N = 10\%$ to 67% for traits with $h^2_N = 25\%$.

**DISCUSSION**

In families of schoolchildren with asthma in Costa Rica, we found significant genetic contributions (heritability) to inter-individual variation in measures of pulmonary function and BDR. The heritability estimates of FEV$_1$ were similar in magnitude to previous studies, but the heritabilities of FEV$_1$/FVC and BDR were lower than have been reported. Because of low heritability, our study had limited statistical power to detect linkage to BDR. However, we had adequate statistical power to detect and found genome-wide suggestive evidence of linkage to post-bronchodilator FEV$_1$, on chromosome 7q34–35, which was improved after inclusion of additional STR markers.

Although no significant or suggestive evidence of linkage was found in the other genome-wide linkage analyses in all subjects, we uncovered potential regions of interest, including chromosome 9p for BDR and chromosome 2q for FEV$_1$/FVC. Despite a small number of smokers and correspondingly limited power, the evidence for linkage for FEV$_1$/FVC (post-bronchodilator) on chromosome 5p approached genome-wide significance.

Several authors have reported genome-wide linkage analyses for spirometric measures of pulmonary function in families ascertained through probands with asthma; however, the present study is the only genome-wide linkage analysis of FEV$_1$ and FEV$_1$/FVC in a Hispanic population. In a study of 2551 members of 533 families in China, Xu et al found the strongest evidence for linkage to FEV$_1$ on chromosomes 10p and 22q. In 591 individuals in 202 Australian families, Ferreira et al showed suggestive evidence of linkage to FEV$_1$ on chromosomes 5q, 8p, 12q, 17q and 20q and to FEV$_1$/FVC on chromosomes 4q, 9q and 12q. Postma et al showed different regions of linkage to FEV$_1$ in genome-wide analyses of all subjects, smokers and non-smokers among 1183 members of 200 Dutch families. They reported genome-wide significant evidence of linkage to FEV$_1$/FVC (both pre-bronchodilator and post-bronchodilator) on chromosome 2q.

There have been no previous reports of suggestive or significant evidence of linkage to FEV$_1$ on chromosome 7q. However, the genome-wide linkage analyses of pulmonary function described above were completed in populations of European and Asian descent. A unique aspect of our study is that we were able to recruit large extended pedigrees of children with asthma because of detailed genealogical records and low migration out of the relatively genetically isolated...
population of the Central Valley of Costa Rica. Our statistical power to detect linkage to lung function measures may have been increased by inclusion of extended pedigrees (which offer more power for linkage analysis of quantitative traits than sib-pair studies with the same sample size) and by founder effects leading to relatively few susceptibility genes for asthma-related traits in Costa Rica. On the other hand, genetic heterogeneity in determinants of lung function among the Spanish and Amerindian founders of the population of the Central Valley may have hindered our statistical power. Although the characteristics of the Costa Rican population may limit the generalisability of our results, it should be noted that the G protein coupled receptor-154 (GPR154) was first identified as a potential asthma-susceptibility gene in a genetically isolated population in Finland and then shown to be relevant in other European nations. Thus, some of our results may be relevant across ethnic groups and others may be more relevant to Costa Ricans and other Hispanic groups of predominant Spanish and Amerindian ancestry.

Genome-wide linkage analyses of pulmonary function have also been performed in families from the general population and in families of probands with severe, early-onset COPD. Several of the regions of interest (LOD > 1.5) in our study are similar to the findings in those studies (table 4), suggesting that some genomic regions are likely to contain genetic variants that influence pulmonary function in normal individuals, in patients with COPD and in those with asthma. Some of these regions may be relevant across different ethnic groups as well. In our analysis, the highest LOD score for FEV1/FVC was found on chromosome 2q. This region overlaps the linkage peaks for FEV1/FVC in families from the general population in Utah and in families from the Boston Early-Onset COPD Study. The FEV1/FVC linkage found in Dutch asthma families is also located on chromosome 2q, but closer to the centromere.

The highest LOD score in any of the genome scans was found for FEV1/FVC (post-bronchodilator) on chromosome 5p13 in an analysis limited to former and current smokers. Despite the limited sample size, the LOD score of 3.27 approached genome-wide significance, possibly identifying a locus (or loci) for smoking-related air flow obstruction in families with a genetic predisposition to asthma, consistent with the Dutch hypothesis, which proposes a common origin for asthma and COPD. Several cadherin genes in asthma and COPD is unknown. Smoking-related air flow obstruction in families with a genetic predisposition to asthma, consistent with the Dutch hypothesis, which proposes a common origin for asthma and COPD. Several cadherin genes (CDH6, 9 and 10) are located on chromosome 5p13. E-cadherin (CDH1), another member of the cadherin family, is a cell adhesion molecule involved in epithelial permeability in allergic asthma. The importance of other cadherin genes in asthma and COPD is unknown.

Although other studies of asthma have analysed both prebronchodilator and post-bronchodilator spirometry, the only previous genome-wide linkage analysis of BDR as a distinct phenotype is from the Boston Early-Onset COPD Study. An analysis limited to chromosome 1q2 examined BDR in families from the Childhood Asthma Management Program Study; the present study is the first reported genome-wide linkage analysis of BDR in families of subjects with asthma. Similar to the Boston Early-Onset COPD Study, we found significant heritability of BDR, although the heritability estimates in our asthma families (h2 = 8.0–10.5% for the three BDR measures) are lower than those found in the COPD families (h2 = 10.1–26.3%). As in our study, no significant linkage for BDR measurements was found in the Boston Early-Onset COPD Study, although regions on chromosomes 3q and 4q had LOD scores of ≥ 1.5.

The ability to detect linkage to measures of BDR may be limited by the day-to-day variability in BDR that is inherent in

### Table 3

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Subjects</th>
<th>Covariates</th>
<th>Chromosome</th>
<th>cM</th>
<th>LOD</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BDRbase</td>
<td>All</td>
<td>None</td>
<td>4</td>
<td>70</td>
<td>1.26</td>
<td>0.008</td>
</tr>
<tr>
<td></td>
<td>Non-smokers</td>
<td>None</td>
<td>10</td>
<td>31</td>
<td>1.59</td>
<td>0.002</td>
</tr>
<tr>
<td></td>
<td>Smokers</td>
<td>Gender</td>
<td>16</td>
<td>66</td>
<td>1.31</td>
<td>0.019</td>
</tr>
<tr>
<td>BDRpred</td>
<td>All</td>
<td>None</td>
<td>9</td>
<td>49</td>
<td>1.25</td>
<td>0.007</td>
</tr>
<tr>
<td></td>
<td>Non-smokers</td>
<td>None</td>
<td>31</td>
<td>69</td>
<td>1.69</td>
<td>0.002</td>
</tr>
<tr>
<td></td>
<td>Smokers</td>
<td>Gender</td>
<td>16</td>
<td>66</td>
<td>1.22</td>
<td>0.018</td>
</tr>
<tr>
<td>BDRabs</td>
<td>All</td>
<td>None</td>
<td>9</td>
<td>49</td>
<td>1.53</td>
<td>0.003</td>
</tr>
<tr>
<td></td>
<td>Non-smokers</td>
<td>None</td>
<td>9</td>
<td>49</td>
<td>1.72</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Smokers</td>
<td>Gender</td>
<td>16</td>
<td>66</td>
<td>1.60</td>
<td>0.012</td>
</tr>
</tbody>
</table>

The maximum LOD score for each analysis is reported. Full results are available in supplementary table 3.

*Definitions of BDR phenotypes: BDRbase = (FEV1post-bronchodilator/FEV1pre-bronchodilator)/100%.
BDRpred = (FEV1post-bronchodilator/FEV1predicted) × 100%.
BDRabs = (FEV1post-bronchodilator−FEV1pre-bronchodilator)/FEV1pre-bronchodilator.

All three BDR variables were log 10 transformed for analysis.

### Table 4

<table>
<thead>
<tr>
<th>Chromosome</th>
<th>Present study</th>
<th>Previous studies</th>
<th>LOD score (cM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>FEV1/FVC, pre-BD</td>
<td>Palmer, 2003*</td>
<td>1.53 (245)</td>
</tr>
<tr>
<td>2</td>
<td>FEV1/FVC, pre-BD</td>
<td>Mallotra, 2003</td>
<td>1.50 (95)</td>
</tr>
<tr>
<td>4</td>
<td>FEV1/FVC, pre-BD</td>
<td>Postma, 2005*</td>
<td>1.50 (95)</td>
</tr>
<tr>
<td>7</td>
<td>FEV1, pre-BD</td>
<td>Ferreira, 2005*</td>
<td>1.53 (11)</td>
</tr>
</tbody>
</table>

*LOD drop support interval.
†log 10 (p Value).
asthma. It is not clear which definition of BDR is most useful in genetic studies, so we used three commonly accepted measures.7 In the analysis, the strongest linkage evidence was for post-bronchodilator FEV1. However, pre-bronchodilator spirometry may be more variable within an individual subject and may be more reflective of asthma symptoms and severity. Because the analyses of pre-bronchodilator and post-bronchodilator spirometry may yield different information on lung development, asthma severity and asthma susceptibility, we chose to perform genome scans on both pre-bronchodilator and post-bronchodilator phenotypes.

Even though we did not find genome-wide significant evidence of linkage for pulmonary function or BDR, the suggestive evidence of linkage to FEV1 on chromosome 7q warrants further investigation. Several plausible asthma candidate genes are located in this region, including the T cell receptor, β subunit (TRB @) and endothelial nitric oxide synthase (NOS3). Polymorphisms in NOS3 have been associated with asthma in some studies but not in others.8–10 As in any genetic analysis, our findings may be due to chance or to causal genetic variants. Although our results were adjusted for multiple testing in the setting of a genome-wide linkage analysis of a single phenotype, we did not adjust for testing of multiple traits because of correlation among lung function phenotypes. Because current methods for association studies cannot be used in a small number of extended pedigrees, we plan to assess our findings further by testing for an association between variants in candidate genes on chromosomes 7q34–35 and FEV1 in nuclear families of children with asthma in Costa Rica.

ACKNOWLEDGEMENTS
We thank the participating families for their enthusiastic cooperation, the members of our field team in Costa Rica (Ligia Sanabria, Ana Castillo, Gabriela Ivankovich, Marcia Solano, Herminia Solano) and the staff at McGill University and the Genome Quebec Innovation Centre (Geneviève Geneau, Alexandre Belisle, Corinne Darmon-Zwag, Frederick Robidoux, David Roquis and Yannick Renaud) and the Channing Laboratory, Brigham and Women’s Hospital (Benedit Bodota, Vimala Chomupong, and Elizabeth Bevilacqua).

REFERENCES


Clinical Evidence—Call for contributors

Clinical Evidence is a regularly updated evidence-based journal available worldwide both as a paper version and on the internet. Clinical Evidence needs to recruit a number of new contributors. Contributors are healthcare professionals or epidemiologists with experience in evidence-based medicine and the ability to write in a concise and structured way.

Areas for which we are currently seeking contributors:

- Pregnancy and childbirth
- Endocrine disorders
- Palliative care
- Tropical diseases

We are also looking for contributors for existing topics. For full details on what these topics are please visit www.clinicalevidence.com/ceweb/contribute/index.jsp

We are always looking for others, so do not let this list discourage you.

Being a contributor involves:

- Selecting from a validated, screened search (performed by in-house Information Specialists) epidemiologically sound studies for inclusion.
- Documenting your decisions about which studies to include on an inclusion and exclusion form, which we keep on file.
- Writing the text to a highly structured template (about 1500-3000 words), using evidence from the final studies chosen, within 8-10 weeks of receiving the literature search.
- Working with Clinical Evidence editors to ensure that the final text meets epidemiological and style standards.
- Updating the text every 12 months using any new, sound evidence that becomes available.

Clinical Evidence in-house team will conduct the searches for contributors; your task is simply to filter out high quality studies and incorporate them in the existing text.

If you would like to become a contributor for Clinical Evidence or require more information about what this involves please send your contact details and a copy of your CV, clearly stating the clinical area you are interested in, to CECommissioning@bmjgroup.com.

Call for peer reviewers

Clinical Evidence also needs to recruit a number of new peer reviewers specifically with an interest in the clinical areas stated above, and also others related to general practice. Peer reviewers are healthcare professionals or epidemiologists with experience in evidence-based medicine. As a peer reviewer you would be asked for your views on the clinical relevance, validity, and accessibility of specific topics within the journal, and their usefulness to the intended audience (international generalists and healthcare professionals, possibly with limited statistical knowledge).

Topics are usually 1500-3000 words in length and we would ask you to review between 2-5 topics per year. The peer review process takes place throughout the year, and out turnaround time for each review is ideally 10-14 days.

If you are interested in becoming a peer reviewer for Clinical Evidence, please complete the peer review questionnaire at www.clinicalevidence.com/ceweb/contribute/peerreviewer.jsp
Genome-wide linkage analysis of pulmonary function in families of children with asthma in Costa Rica


Updated information and services can be found at:
http://thorax.bmj.com/content/62/3/224

These include:

Supplementary Material
Supplementary material can be found at:
http://thorax.bmj.com/content/suppl/2007/02/22/thx.2006.067934.DC1

References
This article cites 37 articles, 7 of which you can access for free at:
http://thorax.bmj.com/content/62/3/224#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Asthma (1782)
Health education (1223)
Smoking (1037)
Tobacco use (1039)
Child health (843)
Airway biology (1100)
Lung function (773)
Tobacco use (youth) (191)
Genetic screening / counselling (88)
Clinical genetics (27)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/